0 (0%) | 03-28 09:09 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 12.2 | 1-year : | 14.25 |
Resists | First : | 10.44 | Second : | 12.2 |
Pivot price | 10.31 | |||
Supports | First : | 10.24 | Second : | 10.11 |
MAs | MA(5) : | 10.37 | MA(20) : | 10.27 |
MA(100) : | 10 | MA(250) : | 9.82 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 67.1 | D(3) : | 73.9 |
RSI | RSI(14): 57.9 | |||
52-week | High : | 10.44 | Low : | 8.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MMU ] has closed below upper band by 29.8%. Bollinger Bands are 45.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 10.39 - 10.43 | 10.43 - 10.48 |
Low: | 10.18 - 10.22 | 10.22 - 10.27 |
Close: | 10.29 - 10.36 | 10.36 - 10.44 |
Thu, 21 Mar 2024
Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher - Yahoo Movies Canada
Fri, 02 Feb 2024
PTI local leader Imran Immu shot dead in Abbottabad - Pakistan Observer
Tue, 16 Jan 2024
Data haul improves immunotherapy response prediction | VUMC Reporter | Vanderbilt University - VUMC Reporter
Thu, 28 Dec 2023
When Will Mendus AB (publ) (STO:IMMU) Breakeven? - Simply Wall St
Fri, 14 Jan 2022
Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade ... - VUMC Reporter
Thu, 14 Oct 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma ... - ScienceDirect.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 55 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 64.6 (%) |
Shares Short | 21 (K) |
Shares Short P.Month | 40 (K) |
EPS | 0.43 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 11.46 |
Profit Margin | 84.1 % |
Operating Margin | 77.8 % |
Return on Assets (ttm) | 1.8 % |
Return on Equity (ttm) | 4.6 % |
Qtrly Rev. Growth | 11.6 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.58 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 39 (M) |
Levered Free Cash Flow | 22 (M) |
PE Ratio | 23.56 |
PEG Ratio | 0 |
Price to Book value | 0.9 |
Price to Sales | 17.73 |
Price to Cash Flow | 14.49 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |